Finally, these findings suggest that inhibitor 2 may help as a lead compound in the development of new cardiovascular disease treatments, and as a prescription enhancer along with typical urea and amide-based sEH inhibitors. The gene discussed is EPHX2; the disease is cardiovascular disorder.